GNLX vs. ONCY, CMRX, PRPH, VTVT, ASRT, RVPH, AFMD, ACRS, IFRX, and BRNS
Should you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Oncolytics Biotech (ONCY), Chimerix (CMRX), ProPhase Labs (PRPH), vTv Therapeutics (VTVT), Assertio (ASRT), Reviva Pharmaceuticals (RVPH), Affimed (AFMD), Aclaris Therapeutics (ACRS), InflaRx (IFRX), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical preparations" industry.
Oncolytics Biotech (NASDAQ:ONCY) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
In the previous week, Genelux had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 8 mentions for Genelux and 6 mentions for Oncolytics Biotech. Genelux's average media sentiment score of 0.97 beat Oncolytics Biotech's score of 0.29 indicating that Oncolytics Biotech is being referred to more favorably in the media.
Oncolytics Biotech received 145 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 68.16% of users gave Oncolytics Biotech an outperform vote.
Oncolytics Biotech has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Genelux has a beta of -1.18, meaning that its stock price is 218% less volatile than the S&P 500.
Oncolytics Biotech has higher earnings, but lower revenue than Genelux. Genelux is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.
6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 11.7% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Genelux's return on equity of -107.11% beat Oncolytics Biotech's return on equity.
Oncolytics Biotech presently has a consensus target price of $4.00, suggesting a potential upside of 241.88%. Genelux has a consensus target price of $34.00, suggesting a potential upside of 787.73%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Genelux is more favorable than Oncolytics Biotech.
Summary
Oncolytics Biotech beats Genelux on 8 of the 15 factors compared between the two stocks.
Get Genelux News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
